{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:12:49Z","timestamp":1794949969752,"version":"4.9.1"},"reference-count":83,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec id=\"ab-nrv230002-1\"><jats:title>Importance<\/jats:title><jats:p>Gene editing using clustered regularly interspaced short palindromic repeats (CRISPR) holds the promise to arrest or cure monogenic disease if it can be determined which genetic change to create without inducing unintended cellular dysfunction and how to deliver this technology to the target organ reliably and safely. Clinical trials for blood and liver disorders, for which delivery of CRISPR is not limiting, show promise, yet no trials have begun for central nervous system (CNS) indications.<\/jats:p><\/jats:sec><jats:sec id=\"ab-nrv230002-2\"><jats:title>Observations<\/jats:title><jats:p>The CNS is arguably the most challenging target given its innate exclusion of large molecules and its defenses against bacterial invasion (from which CRISPR originates). Herein, the types of CRISPR editing (DNA cutting, base editing, and templated repair) and how these are applied to different genetic variants are summarized. The challenges of delivering genome editors to the CNS, including the viral and nonviral delivery vehicles that may ultimately circumvent these challenges, are discussed. Also, ways to minimize the potential in vivo genotoxic effects of genome editors through delivery vehicle design and preclinical off-target testing are considered. The ethical considerations of germline editing, a potential off-target outcome of any gene editing therapy, are explored. The unique regulatory challenges of a human-specific therapy that cannot be derisked solely in animal models are also discussed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-nrv230002-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>An understanding of both the potential benefits and challenges of CRISPR gene therapy better informs the scientific, clinical, regulatory, and timeline considerations of developing CRISPR gene therapy for neurologic diseases.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.4983","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T16:31:28Z","timestamp":1706545888000},"page":"283","source":"Crossref","is-referenced-by-count":41,"title":["Building CRISPR Gene Therapies for the Central Nervous System"],"prefix":"10.1001","volume":"81","author":[{"given":"Sally E.","family":"Salomonsson","sequence":"first","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Department of Neurology, Memory and Aging Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire D.","family":"Clelland","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Department of Neurology, Memory and Aging Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5819","key":"nrv230002r1","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes.","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"issue":"6096","key":"nrv230002r2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"nrv230002r3","doi-asserted-by":"publisher","author":"Reardon","journal-title":"Nature","DOI":"10.1038\/nature.2016.20137"},{"issue":"7613","key":"nrv230002r4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nature.2016.20302","article-title":"Chinese scientists to pioneer first human CRISPR trial.","volume":"535","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"issue":"6","key":"nrv230002r5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis.","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"nrv230002r6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u00df-thalassemia.","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"nrv230002r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"nrv230002r8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy.","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"nrv230002r9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS.","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"nrv230002r10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","article-title":"Advances in genome editing through control of DNA repair pathways.","volume":"21","author":"Yeh","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"1","key":"nrv230002r11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations.","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat Commun"},{"issue":"42","key":"nrv230002r12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing.","volume":"8","author":"Park","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"nrv230002r13","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1038\/s41467-021-26097-y","article-title":"Whole chromosome loss and genomic instability in mouse embryos after CRISPR-Cas9 genome editing.","volume":"12","author":"Papathanasiou","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"nrv230002r14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice.","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol Cell"},{"issue":"4","key":"nrv230002r15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.neuron.2017.10.004","article-title":"Virus-mediated genome editing via homology-directed repair in mitotic and postmitotic cells in mammalian brain.","volume":"96","author":"Nishiyama","year":"2017","journal-title":"Neuron"},{"issue":"7785","key":"nrv230002r16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA.","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"4","key":"nrv230002r17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases.","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"7603","key":"nrv230002r18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"5","key":"nrv230002r19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing.","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"6437","key":"nrv230002r20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos.","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"issue":"6437","key":"nrv230002r21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.aaw7166","article-title":"Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice.","volume":"364","author":"Jin","year":"2019","journal-title":"Science"},{"key":"nrv230002r22","doi-asserted-by":"publisher","author":"Fiumara","journal-title":"Nat Biotechnol","DOI":"10.1038\/s41587-023-01915-4"},{"issue":"1","key":"nrv230002r23","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-023-37507-8","article-title":"Prime editing with genuine Cas9 nickases minimizes unwanted indels.","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"nrv230002r24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","article-title":"Prime editing: advances and therapeutic applications.","volume":"41","author":"Zhao","year":"2023","journal-title":"Trends Biotechnol"},{"issue":"10","key":"nrv230002r25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA-guided activation of endogenous human genes.","volume":"10","author":"Maeder","year":"2013","journal-title":"Nat Methods"},{"issue":"3","key":"nrv230002r26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-scale CRISPR-mediated control of gene repression and activation.","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"issue":"17","key":"nrv230002r27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMcibr1809628","article-title":"Hemoglobinopathies in the fetal position.","volume":"379","author":"Pasricha","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"nrv230002r28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cpt.2531","article-title":"Translational approaches for brain delivery of biologics via cerebrospinal fluid.","volume":"111","author":"Sadekar","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"3-4","key":"nrv230002r29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration.","volume":"34","author":"Chen","year":"2023","journal-title":"Hum Gene Ther"},{"key":"nrv230002r30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain.","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"nrv230002r31","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/ijms15021812","article-title":"Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles\u2019 brain permeability in association with particle size and surface modification.","volume":"15","author":"Hanada","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"13","key":"nrv230002r32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2217\/nnm-2017-0022","article-title":"The effect of nanoparticle size on the ability to cross the blood-brain barrier: an in vivo study.","volume":"12","author":"Betzer","year":"2017","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"nrv230002r33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12951-015-0075-7","article-title":"The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model.","volume":"13","author":"Shilo","year":"2015","journal-title":"J Nanobiotechnology"},{"key":"nrv230002r34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination.","volume":"240","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"issue":"12","key":"nrv230002r35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery.","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"27","key":"nrv230002r36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv230002r37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"nrv230002r38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.molmed.2021.03.003","article-title":"Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines.","volume":"27","author":"Swingle","year":"2021","journal-title":"Trends Mol Med"},{"issue":"6","key":"nrv230002r39","doi-asserted-by":"publisher","DOI":"10.1002\/adma.v35.6","article-title":"Overcoming the blood-brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules.","volume":"35","author":"Wang","year":"2023","journal-title":"Adv Mater"},{"issue":"16","key":"nrv230002r40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy.","volume":"8","author":"Zou","year":"2022","journal-title":"Sci Adv"},{"key":"nrv230002r41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis.","volume":"13","author":"Shen","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"nrv230002r43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial.","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol Ther"},{"issue":"13-14","key":"nrv230002r44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy.","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"1","key":"nrv230002r45","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks.","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"key":"nrv230002r46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A self-deleting AAV-CRISPR system for in vivo genome editing.","volume":"12","author":"Li","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"nrv230002r47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41587-021-01009-z","article-title":"Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus.","volume":"40","author":"Kim","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"16","key":"nrv230002r48","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle.","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"nrv230002r49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/ng0598-13","article-title":"The kinetics of rAAV integration in the liver.","volume":"19","author":"Miao","year":"1998","journal-title":"Nat Genet"},{"key":"nrv230002r50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.omtm.2021.09.017","article-title":"Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal.","volume":"23","author":"Marc\u00f3","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"nrv230002r51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 protein.","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6","key":"nrv230002r52","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9.","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"issue":"9","key":"nrv230002r53","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing.","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"nrv230002r55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"nrv230002r56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","article-title":"Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR.","volume":"17","author":"Haeussler","year":"2016","journal-title":"Genome Biol"},{"issue":"6","key":"nrv230002r57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat Methods"},{"issue":"6","key":"nrv230002r58","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nmeth.4284","article-title":"Mapping the genomic landscape of CRISPR-Cas9 cleavage.","volume":"14","author":"Cameron","year":"2017","journal-title":"Nat Methods"},{"issue":"2","key":"nrv230002r59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"11","key":"nrv230002r60","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity.","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"10","key":"nrv230002r61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia.","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"668","key":"nrv230002r62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"nrv230002r65","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs.","author":"Davis","journal-title":"Nat Biotechnol"},{"issue":"5","key":"nrv230002r66","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice.","volume":"7","author":"Everette","year":"2023","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"nrv230002r67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases.","volume":"6","author":"Jang","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"7753","key":"nrv230002r75","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/d41586-019-01284-6","article-title":"Manage risk of accidental gene editing of germline.","volume":"568","author":"Monckton","year":"2019","journal-title":"Nature"},{"issue":"7747","key":"nrv230002r76","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/d41586-019-00726-5","article-title":"Adopt a moratorium on heritable genome editing.","volume":"567","author":"Lander","year":"2019","journal-title":"Nature"},{"issue":"7733","key":"nrv230002r77","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41586-018-07545-0","article-title":"Genome-edited baby claim provokes international outcry.","volume":"563","author":"Cyranoski","year":"2018","journal-title":"Nature"},{"issue":"7789","key":"nrv230002r78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/d41586-020-00001-y","article-title":"What CRISPR-baby prison sentences mean for research.","volume":"577","author":"Cyranoski","year":"2020","journal-title":"Nature"},{"issue":"7910","key":"nrv230002r79","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-022-04712-2","article-title":"Genetic and chemotherapeutic influences on germline hypermutation.","volume":"605","author":"Kaplanis","year":"2022","journal-title":"Nature"},{"issue":"1","key":"nrv230002r80","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.1038\/ncomms7684","article-title":"The genome-wide effects of ionizing radiation on mutation induction in the mammalian germline.","volume":"6","author":"Adewoye","year":"2015","journal-title":"Nat Commun"},{"issue":"3","key":"nrv230002r81","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models.","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"nrv230002r82","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg6276","article-title":"FDA no longer needs to require animal tests before human drug trials.","author":"Wadman","journal-title":"Science"},{"issue":"6","key":"nrv230002r83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/crispr.2020.0053","article-title":"Evaluation of homology-independent CRISPR-Cas9 off-target assessment methods.","volume":"3","author":"Chaudhari","year":"2020","journal-title":"CRISPR J"},{"key":"nrv230002r42","doi-asserted-by":"crossref","unstructured":"Lek? A, Wong? B, Keeler? A, . Unexpected death of a Duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-1 delivered CRISPR-transactivator.? medRxiv. Preprint posted online May 18, 2023. doi:10.1101\/2023.05.16.23289881","DOI":"10.1101\/2023.05.16.23289881"},{"key":"nrv230002r54","unstructured":"Intellia Therapeutics announces new positive clinical data from phase 1 study of NTLA-2002, an investigational in vivo CRISPR genome editing treatment for hereditary angioedema (HAE). News release. Intellia Therapeutics. June 11, 2023. Accessed July 20, 2023. https:\/\/ir.intelliatx.com\/node\/10936\/pdf"},{"key":"nrv230002r63","unstructured":"BEACON: a study evaluating the safety and efficacy of BEAM-101 in patients with severe sickle cell disease (BEACON). ClinicalTrials.gov identifier: NCT05456880. Updated November 8, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05456880"},{"key":"nrv230002r64","unstructured":"A study of VERVE-101 in patients with familial hypercholesterolemia and cardiovascular disease. ClinicalTrials.gov identifier: NCT05398029. Updated May 16, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05398029"},{"key":"nrv230002r68","unstructured":"FDA approves first gene therapies to treat patients with sickle cell disease. News release. US Food and Drug Administration. December 8, 2023. Accessed December 26, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease"},{"key":"nrv230002r69","unstructured":"Intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of NTLA-2001, an investigational CRISPR therapy for the treatment of transthyretin (ATTR) amyloidosis at the American Heart Association Scientific Sessions 2022. News release. Intellia Therapeutics. November 5, 2022. Accessed July 24, 2023. https:\/\/ir.intelliatx.com\/node\/10536\/pdf"},{"key":"nrv230002r70","unstructured":"Intellia and Regeneron announce updated phase 1 data demonstrating a single dose of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis, resulted in rapid, deep and sustained reduction in disease-causing protein. News release. Intellia Therapeutics. February 28, 2022. Accessed July 24, 2023. https:\/\/ir.intelliatx.com\/node\/10101\/pdf"},{"key":"nrv230002r71","unstructured":"Study of EBT-101 in aviremic HIV-1 infected adults on stable ART. ClinicalTrials.gov identifier: NCT05144386. Updated November 7, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05144386"},{"key":"nrv230002r72","unstructured":"A study of LBP-EC01 in the treatment of acute uncomplicated UTI caused by multi-drug resistant E. coli (ELIMINATE Trial) (ELIMINATE). ClinicalTrials.gov identifier: NCT05488340. Updated September 26, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05488340"},{"key":"nrv230002r73","unstructured":"A study investigating the safety, recovery, and pharmacodynamics of multiple oral administrations of SNIPR001 in healthy subjects. ClinicalTrials.gov identifier: NCT05277350. Updated May 17, 2023. Accessed November 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05277350"},{"key":"nrv230002r74","unstructured":"Dorval? A; Verve Therapeutics. Form 8-K. Published December 5, 2022. Accessed July 21, 2023. https:\/\/ir.vervetx.com\/static-files\/ff045a43-e13f-4f30-b651-c9946c0055dd"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2814366\/jamaneurology_salomonsson_2024_rv_230002_1709917424.74302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T15:03:09Z","timestamp":1710169389000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2814366"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.4983","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}